利妥昔单抗静脉快速输注中国专家共识(2020年版)  

Chinese expert consensus on rapid infusion of rituximab(2020 version)

作　　者：中国老年保健协会淋巴瘤专业委员会 中华医学会血液学分会 黄慧强[2] 杨海燕[3] 许景艳[4] 吴俣 高岩[6] Lymphoma Committee of Chinese Aging Well Association;Chinese Society of Hematology,Chinese Medical Association;Huang Huiqiang(不详;Department of Oncology,Sun Yat-sen University Cancer Center,Guangzhou 510060,China)

机构地区：[1]不详 [2]中山大学肿瘤防治中心肿瘤内科,广州510060 [3]浙江省肿瘤医院 [4]南京鼓楼医院 [5]四川大学华西医院 [6]中山大学肿瘤防治中心

出　　处：《白血病．淋巴瘤》2021年第1期1-4,共4页Journal of Leukemia & Lymphoma

摘　　要：利妥昔单抗上市20多年以来,在临床实践中疗效和安全性良好。美国食品药品管理局(FDA)于2012年批准了利妥昔单抗的静脉快速输注用于第2个及后续疗程。目前,利妥昔单抗90 min静脉快速输注方案已在国外成熟应用,美国国立综合癌症网络(NCCN)指南中也推荐第1个疗程利妥昔单抗输注未出现输注反应的患者,后续疗程可进行利妥昔单抗90min静脉快速输注。我国也有研究数据证实了利妥昔单抗90min静脉快速输注方案的安全性和耐受性。因此,基于国内外循证医学证据,为了提高患者的就诊质量以及节约医疗成本,本专家共识推荐,对于首次输注未发生明显不良反应的患者,后续疗程可使用利妥昔单抗90 min静脉快速输注方案。Rituximab has received marketing authorization for more than 20 years and has good efficacy and safety in clinical practice.The U.S.Food and Drug Administration(FDA)approved a rapid infusion of rituximab for the second and subsequent cycles of treatment in 2012.Nowadays,the 90-minute rapid infusion of rituximab in foreign countries has been maturely applied.The National Comprehensive Cancer Network(NCCN)guidelines also recommend a 90-minute rapid infusion of rituximab for the second and subsequent cycles of rituximab to patients who do not experience infusion-related reactions during the first cycle of rituximab infusion.In China,there are emerging research data confirming the safety and tolerability of the 90-minute rapid infusion of rituximab.Therefore,based on evidences from evidence-based medicine at home and abroad,in order to improve the quality of patients'hospital visits and further save healthcare costs,this expert consensus recommends the use of 90-minute rapid infusion of rituximab for patients who have no obvious adverse reactions during the first cycle of infusion.

关 键 词：淋巴瘤 非霍奇金 利妥昔单抗 静脉快速输注 输注相关反应 

分 类 号：R730.5[医药卫生—肿瘤]